HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Review UK’s ‘Onerous’ CBD Novel Food Process, Says Parliamentary Group

Executive Summary

The UK Food Standards Agency should look again at its novel food process for CBD to level the playing field for home-grown companies competing against foreign investment, according to a group of UK politicians. 

You may also be interested in...



FSA Review Could Shake Up UK's Approach To Novel Foods

The Food Standards Agency is critically evaluating the UK's novel foods authorization process to ensure it strikes the optimal balance between promoting innovation and protecting consumers. Assessing regulatory approaches to novel foods outside the EU is central to the review, which has been prompted by Brexit.

UK FSA Finalizes Public CBD List Comprising Almost 12,000 Products

The UK Food Standards Agency has published the final update to its public CBD list following what Canna Consultants' Matt Lawson describes as a regulatory “baptism of fire.” There are now 11,908 products permitted to remain on the UK market once those classed as “removed” are taken into account. These products will either progress to the “validated” stage of the UK's novel food process or also be removed.
 

CBD Supplements Safety: EU Two Years Behind UK

When it comes to assessing the safety of CBD in foods, the EU appears to be lagging behind the UK. Food Standards Agency CEO Emily Miles has noted that EFSA recently reached the same conclusions as the UK’s Committee on Toxicity did two years ago: there are still evidence gaps relating to CBD as a food. This may reassure UK operators that with the FSA further along in the assessment process it will not follow EFSA in suspending CBD novel food applications - but as expert Greer Deal notes, it's too soon to say. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel